Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . OLX-07010 has been well characterised through an extensive program of pre-clinical toxicology and metabolism testing. .
Drug Discovery World
FEBRUARY 22, 2024
With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.
Drug Discovery World
AUGUST 15, 2023
We suggest a new generation of screening assays, that better recapitulate the electrophysiology of the whole human heart, may allow better decisions across research and development. This article will review the challenges and explore the novel electrophysiological solutions required to better calibrate risk.
Expert insights. Personalized for you.
52 
Let's personalize your content